These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 15756094)
1. Tegaserod is safe, well tolerated and effective in the treatment of patients with non-diarrhoea irritable bowel syndrome. Fried M; Beglinger C; Bobalj NG; Minor N; Coello N; Michetti P; Eur J Gastroenterol Hepatol; 2005 Apr; 17(4):421-7. PubMed ID: 15756094 [TBL] [Abstract][Full Text] [Related]
2. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489 [TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation. Fock KM; Wagner A; J Gastroenterol Hepatol; 2007 Aug; 22(8):1190-8. PubMed ID: 17524039 [TBL] [Abstract][Full Text] [Related]
4. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Nyhlin H; Bang C; Elsborg L; Silvennoinen J; Holme I; Rüegg P; Jones J; Wagner A Scand J Gastroenterol; 2004 Feb; 39(2):119-26. PubMed ID: 15000272 [TBL] [Abstract][Full Text] [Related]
5. Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review. Rivkin A Clin Ther; 2003 Jul; 25(7):1952-74. PubMed ID: 12946544 [TBL] [Abstract][Full Text] [Related]
6. Review of tegaserod in the treatment of irritable bowel syndrome. Patel S; Berrada D; Lembo A Expert Opin Pharmacother; 2004 Nov; 5(11):2369-79. PubMed ID: 15500384 [TBL] [Abstract][Full Text] [Related]
8. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Evans BW; Clark WK; Moore DJ; Whorwell PJ Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807 [TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of tegaserod in irritable bowel syndrome management. Berardi RR J Am Pharm Assoc (2003); 2004; 44(1):41-51. PubMed ID: 14965152 [TBL] [Abstract][Full Text] [Related]
10. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Kellow J; Lee OY; Chang FY; Thongsawat S; Mazlam MZ; Yuen H; Gwee KA; Bak YT; Jones J; Wagner A Gut; 2003 May; 52(5):671-6. PubMed ID: 12692051 [TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Novick J; Miner P; Krause R; Glebas K; Bliesath H; Ligozio G; Rüegg P; Lefkowitz M Aliment Pharmacol Ther; 2002 Nov; 16(11):1877-88. PubMed ID: 12390096 [TBL] [Abstract][Full Text] [Related]
12. Tegaserod for the treatment of irritable bowel syndrome. Evans BW; Clark WK; Moore DJ; Whorwell PJ Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049 [TBL] [Abstract][Full Text] [Related]
13. Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome. Hasler WL; Schoenfeld P Drug Saf; 2004; 27(9):619-31. PubMed ID: 15230644 [TBL] [Abstract][Full Text] [Related]
14. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome]. Tegaserod Clinical Research Group Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):88-90. PubMed ID: 12783702 [TBL] [Abstract][Full Text] [Related]
15. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. Chey WD; Paré P; Viegas A; Ligozio G; Shetzline MA Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346 [TBL] [Abstract][Full Text] [Related]
16. Benefit-risk assessment of tegaserod in irritable bowel syndrome. Lea R; Whorwell PJ Drug Saf; 2004; 27(4):229-42. PubMed ID: 15003035 [TBL] [Abstract][Full Text] [Related]
17. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Müller-Lissner SA; Fumagalli I; Bardhan KD; Pace F; Pecher E; Nault B; Rüegg P Aliment Pharmacol Ther; 2001 Oct; 15(10):1655-66. PubMed ID: 11564007 [TBL] [Abstract][Full Text] [Related]
18. Tegaserod for the Treatment of Irritable Bowel Syndrome. Madia VN; Messore A; Saccoliti F; Tudino V; De Leo A; De Vita D; Bortolami M; Scipione L; Pindinello I; Costi R; Di Santo R Antiinflamm Antiallergy Agents Med Chem; 2020; 19(4):342-369. PubMed ID: 31518227 [TBL] [Abstract][Full Text] [Related]
19. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women. Wagstaff AJ; Frampton JE; Croom KF Drugs; 2003; 63(11):1101-20. PubMed ID: 12749744 [TBL] [Abstract][Full Text] [Related]